19/07/2017

FIDIA FARMACEUTICI S.P.A. LEADS EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021, according to a research study by RnR Market Research (1).
 

“Fidia Farmaceutici has invested in research and development of hyaluronic acid-based products for more than 70 years. Today, Fidia is growing its product portfolio with new, innovative solutions to meet challenges in the field of osteoarthritis using science, our legacy and our drive.”

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Other product websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.